MISE Foreign visitors
Campus Formativo Newsletter Promozionale Sala Stampa Export Club
Home > Notizie Italia/Estero!
Panorama Internazionale

13 OTTOBRE 2017

10:34 - Corea del Sud


(ICE) - ROMA, 13 OTT -

SK Chemicals can sell its zoster virus vaccine beginning later this year.

The pharmaceutical and chemical goods manufacturer said Wednesday it has been given the green light to sell Sky Zoster for the prevention of herpes zoster by the Ministry of Food and Drug Safety.

The chemical arm of SK Group is the first Korean firm to gain approval from the health authorities to sell such a vaccine and the second in the world following Merck, the global giant based in Germany, whose Zostavax went on sale here in 2013.

In addition, the latest marketing approval helps Korea reach 50 percent self-sufficiency in vaccine production – 14 out of 28 permissible here.

SK plans to supply the vaccine to local hospitals starting at the end of the year, which is expected to break the Zostavax monopoly in Korea.

Herpes zoster, also known as shingles, typically shows up as a painful rash that develops on the body as a result of the reactivation of the zoster virus.

It sometimes manifests as nerve pain that can last for months or even year.

Sky Zoster, categorized as a premium vaccine, will be available for 180,000 won to 200.000 won ($158 to $176).

According to the company, once inoculated, its precautionary effect can last for up to 10 years.

The local shingles vaccine market currently stands at around 80 billion won, with the global market estimated at about $685 million, industry tracker Datamonitor noted.

“Following the world’s first cell-culture influenza vaccine, Sky Cell Flu Quadrivalent in 2016, we have successfully developed another good vaccine with our own technology, “the company’s CEO Park Man-hoon said.

“We will focus on developing various premium vaccines to help Korea emerge as a vaccine powerhouse.”



Notizie Italia/Estero